Biohaven Announces Proposed $250M Public Offering Of Common Shares
Biohaven Announces Proposed $250M Public Offering Of Common Shares
Biohaven Ltd. (NYSE:BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced that it has commenced an underwritten public offering of $250 million of its common shares. All of the common shares to be sold in the offering will be offered by Biohaven. In addition, Biohaven expects to grant the underwriter a 30-day option to purchase up to an additional $37.5 million of common shares at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Biohaven intends to use the net proceeds received from the offering for general corporate purposes.
Biohaven有限公司（紐交所：BHVN）是一家全球臨床階段生物製藥公司，專注於發現、開發和商業化治療各種罕見和常見疾病的變革性療法。今日宣佈已啓動25000萬美元普通股的在下市場公開發售。所有將在本次發售中出售的普通股由Biohaven提供。此外，Biohaven預計將授予承銷商在公開發行價格下的30天認購權，認購額最高爲3750萬美元，扣除承銷折扣和佣金。本次發售受市場和其他條件影響，不能保證發售將在何時或何時完成，或實際發售規模或條件。Biohaven打算將所籌款項用於一般公司用途。
J.P. Morgan and Morgan Stanley are acting as book-running managers of the offering.
摩根士丹利和摩根大通正在擔任本次發行的包銷經辦。
譯文內容由第三人軟體翻譯。